Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs ONC 201 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Oncoceutics
- 21 Feb 2018 Planned number of patients changed from 53 to 76.
- 21 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 13 Nov 2017 Results from predictive and pharmacodynamic biomarker analyses presented in an Oncoceutics media release.